Spalt praktisch Partikel puma biotechnology neratinib Industrie Maler Unbemannt
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Inc. - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS
Puma Biotechnology: Waiting For Commercial Numbers To Catch Up To Clinical Data (NASDAQ:PBYI) | Seeking Alpha
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology's Neratinib Set To Target Extended Adjuvant Opportunity (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Receives US FDA Approval of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
PUMA BIOTECHNOLOGY, INC.
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | SpringerLink
Dose escalation for mitigating diarrhea: Ranked tolerability assessment of antidiarrheal regimens in patients receiving neratin
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 | Business Wire
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting
HER2+ Breast Cancer Patients' Access to Neratinib Expanded Through Puma's EAP
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
PUMA BIOTECHNOLOGY, INC.
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics